Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. The Company was founded in 1988 and is engaged in developing and commercializing products to enhance human health and wellbeing. Humanetics entered the field of radiation modulators in 2003, through a cooperative research program with the Armed Forces Radiobiology Research Institute (AFRRI). AFRRI's mission is the discovery and early development of drugs that can protect warfighters from the harmful effects of radiation. Humanetics began working with AFRRI to test an array of drug candidates using their highly developed capabilities. From this program, BIO 300 emerged as a lead candidate and the underlying technology was in-licensed from the Department of Defense to Humanetics. In the ensuing years, the Company has progressed this program into clinical stage with a primary focus on improving the treatment outcomes for patients receiving radiation treatment of solid tumors. Humanetics has three open INDs for BIO 300. We have active clinical programs focused on medical countermeasures, solid tumor radiotherapy and in COVID-19.
The Company's scientific team has strong partnerships with private and public research institutions that have unique capabilities to test radiation modulators. Click here to learn more about our collaboration partners. Funding for our programs has come from private equity sources as well as multiple government appropriations, grants and contracts across several federal agencies. Humanetics has received over $36 million in non-dilutive funding from The National Cancer Institute (NCI), The National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), The National Space Biomedical Research Institute (NSBRI), the National Aeronautics and Space Administration (NASA) and the Department of Defense (DoD).